The prognosis of metastatic colorectal cancer (mCRC) remains poor regardless of the
advances obtained in recent years with new therapeutic agents, surgical procedures, and …

The epidermal growth factor receptor (EGFR) has become an important target in cancer
treatment. In consequence, drugs directed at this and other molecular targets are an …

The epidermal growth factor receptor (EGFR) is recognized as an important player in
colorectal cancer (CRC) initiation and progression. This membrane-bound receptor tyrosine …

Colorectal cancer (CRC) is the third most common cancer worldwide, with approximately 1
million new cases diagnosed every year. It is estimated that approximately half of the …

The epidermal growth factor receptor (EGFR) has been validated as a therapeutic target in
several human tumours, including colorectal cancer (CRC). Although EGFR expression is …

Mutations in K-Ras are observed in approximately 40% of colon tumours. This has
significant implications for predicting likelihood of response to the antibody-based EGFR …

Recent insights into the molecular pathogenesis of colorectal cancer (CRC) have given rise
to specific targetdirected therapies, including monoclonal antibodies (mAb) against …

In a 1990 review, Fearon and Vogelstein1 presented a model for the genetic basis of
colorectal neoplasia, stating that colorectal cancer (CRC) development requires the …

The discovery of the key role of the epidermal growth factor receptor (EGFR) and its
downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has …

Some of the most significant therapeutic advances in the treatment of cancer have occurred
in the management of colorectal metastases. The introduction of new cytotoxic …